These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 27033672)

  • 1. Cost-effectiveness of Gemcitabine Plus Modern Radiotherapy in Locally Advanced Pancreatic Cancer.
    Leung HW; Chan AL; Muo CH
    Clin Ther; 2016 May; 38(5):1174-83. PubMed ID: 27033672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of modern radiotherapy techniques in locally advanced pancreatic cancer.
    Murphy JD; Chang DT; Abelson J; Daly ME; Yeung HN; Nelson LM; Koong AC
    Cancer; 2012 Feb; 118(4):1119-29. PubMed ID: 21773972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma.
    Leung HW; Liu CF; Chan AL
    Radiat Oncol; 2016 May; 11():69. PubMed ID: 27193904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic Evaluation for USA of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer.
    Gharaibeh M; McBride A; Alberts DS; Slack M; Erstad B; Alsaid N; Bootman JL; Abraham I
    Pharmacoeconomics; 2018 Oct; 36(10):1273-1284. PubMed ID: 29948964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic evaluation for the US of nab-paclitaxel plus gemcitabine versus FOLFIRINOX versus gemcitabine in the treatment of metastatic pancreas cancer.
    Gharaibeh M; McBride A; Bootman JL; Patel H; Abraham I
    J Med Econ; 2017 Apr; 20(4):345-352. PubMed ID: 27919186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of gemcitabine, S-1 and gemcitabine plus S-1 for treatment of advanced pancreatic cancer based on GEST study.
    Zhou J; Zhao R; Wen F; Zhang P; Tang R; Du Z; He X; Zhang J; Li Q
    Med Oncol; 2015 Apr; 32(4):121. PubMed ID: 25788034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma.
    Herman JM; Chang DT; Goodman KA; Dholakia AS; Raman SP; Hacker-Prietz A; Iacobuzio-Donahue CA; Griffith ME; Pawlik TM; Pai JS; O'Reilly E; Fisher GA; Wild AT; Rosati LM; Zheng L; Wolfgang CL; Laheru DA; Columbo LA; Sugar EA; Koong AC
    Cancer; 2015 Apr; 121(7):1128-37. PubMed ID: 25538019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic Evaluation for the UK of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer.
    Gharaibeh M; McBride A; Alberts DS; Erstad B; Slack M; Alsaid N; Bootman JL; Abraham I
    Pharmacoeconomics; 2018 Nov; 36(11):1333-1343. PubMed ID: 29981004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic evaluation for the UK of nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreas cancer.
    Gharaibeh M; McBride A; Bootman JL; Abraham I
    Br J Cancer; 2015 Apr; 112(8):1301-5. PubMed ID: 25791875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erlotinib plus gemcitabine versus gemcitabine for pancreatic cancer: real-world analysis of Korean national database.
    Shin S; Park CM; Kwon H; Lee KH
    BMC Cancer; 2016 Jul; 16():443. PubMed ID: 27400734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of treatments for metastatic pancreatic cancer based on PRODIGE and MPACT trials.
    Zhou J; Zhao R; Wen F; Zhang P; Wu Y; Tang R; Chen H; Zhang J; Li Q
    Tumori; 2016 Jun; 2016(3):294-300. PubMed ID: 27056335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-World Cost-Effectiveness of First-Line Gemcitabine Plus Nab-Paclitaxel vs FOLFIRINOX in Patients With Advanced Pancreatic Cancer.
    Arciero V; Luo J; Parmar A; Dai WF; Beca JM; Raphael MJ; Isaranuwatchai W; Habbous S; Tadrous M; Earle CC; Biagi JJ; Mittmann N; Arias J; Gavura S; Chan KKW
    JNCI Cancer Spectr; 2022 Jul; 6(4):. PubMed ID: 35758620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcomes and prognostic factors of stereotactic body radiation therapy combined with gemcitabine plus capecitabine for locally advanced unresectable pancreatic cancer.
    Shen ZT; Zhou H; Li AM; Ji XQ; Jiang CC; Yuan X; Li B; Zhu XX; Huang GC
    J Cancer Res Clin Oncol; 2020 Feb; 146(2):417-428. PubMed ID: 31667573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis.
    Choi JG; Nipp RD; Tramontano A; Ali A; Zhan T; Pandharipande P; Dowling EC; Ferrone CR; Hong TS; Schrag D; Fernandez-Del Castillo C; Ryan DP; Kong CY; Hur C
    Oncologist; 2019 Jul; 24(7):945-954. PubMed ID: 30559125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. S-1 or gemcitabine adjuvant therapy in resected pancreatic cancer: a cost-effectiveness analysis based on the JASPAC-01 trial.
    Liao W; Huang J; Zhu G; Zhou J; Wen F; Zhang P; Zhou K; Wu Q; Wang X; Gou H; Li Q
    Expert Rev Pharmacoecon Outcomes Res; 2020 Feb; 20(1):133-138. PubMed ID: 31597496
    [No Abstract]   [Full Text] [Related]  

  • 16. The real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu-positive early breast cancer in Taiwan.
    Lang HC; Chen HW; Chiou TJ; Chan AL
    J Med Econ; 2016 Oct; 19(10):923-7. PubMed ID: 27135256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of SBRT versus IMRT: an emerging initial radiation treatment option for organ-confined prostate cancer.
    Hodges JC; Lotan Y; Boike TP; Benton R; Barrier A; Timmerman RD
    Am J Manag Care; 2012 May; 18(5):e186-93. PubMed ID: 22694113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of SBRT versus IMRT for low-risk prostate cancer.
    Sher DJ; Parikh RB; Mays-Jackson S; Punglia RS
    Am J Clin Oncol; 2014 Jun; 37(3):215-21. PubMed ID: 23275277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness of Nab-Paclitaxel and Gemcitabine Versus Gemcitabine Monotherapy for Patients with Unresectable Metastatic Pancreatic Cancer in Japan.
    Morimoto K; Moriwaki K; Kaneyasu T; Nakayama H; Shimozuma K
    Value Health Reg Issues; 2022 Mar; 28():54-60. PubMed ID: 34800832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using economic analysis to evaluate the potential of multimodality therapy for elderly patients with locally advanced pancreatic cancer.
    Krzyzanowska MK; Earle CC; Kuntz KM; Weeks JC
    Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):211-8. PubMed ID: 17189071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.